Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials

Andrew Bentall, Byron H. Smith, Manuel Moreno Gonzales, Keisha Bonner, Walter D. Park, Lynn D. Cornell, Patrick G. Dean, Carrie Schinstock, Richard Borrows, Carmen Lefaucheur, Alexandre Loupy, Mark D Stegall

Research output: Contribution to journalArticle

Abstract

Predicting which renal allografts will fail and the likely cause of failure is important in clinical trial design to either enrich patient populations to be or as surrogate efficacy endpoints for trials aimed at improving long-term graft survival. This study tests our previous Birmingham-Mayo model (termed the BirMay Predictor) developed in a low-risk kidney transplant population in order to predict the outcome of patients with donor specific alloantibody (DSA) at the time of transplantation and identify new factors to improve graft loss prediction in DSA+ patients. We wanted define ways to enrich the population for future therapeutic intervention trials. The discovery set included 147 patients from Mayo Cohort and the validation set included 111 patients from the Paris Cohort—all of whom had DSA at the time of transplantation. The BirMay predictor performed well predicting 5-year outcome well in DSA+ patients (Mayo C statistic = 0.784 and Paris C statistic = 0.860). Developing a new model did not improve on this performance. A high negative predictive value of greater than 90% in both cohorts excluded allografts not destined to fail within 5 years. We conclude that graft-survival models including histology predict graft loss well, both in DSA+ cohorts as well as DSA- patients.

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StatePublished - Jan 1 2019

Fingerprint

Isoantibodies
Tissue Donors
Clinical Trials
Transplants
Antibodies
Paris
Graft Survival
Allografts
Transplantation
Population
Kidney
Histology
Biomarkers

Keywords

  • alloantibody
  • clinical research/practice
  • kidney (allograft) function/dysfunction
  • kidney transplantation/nephrology
  • pathology/histopathology
  • protocol biopsy
  • risk assessment/risk stratification

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor : Implications for clinical trials. / Bentall, Andrew; Smith, Byron H.; Gonzales, Manuel Moreno; Bonner, Keisha; Park, Walter D.; Cornell, Lynn D.; Dean, Patrick G.; Schinstock, Carrie; Borrows, Richard; Lefaucheur, Carmen; Loupy, Alexandre; Stegall, Mark D.

In: American Journal of Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Bentall, Andrew ; Smith, Byron H. ; Gonzales, Manuel Moreno ; Bonner, Keisha ; Park, Walter D. ; Cornell, Lynn D. ; Dean, Patrick G. ; Schinstock, Carrie ; Borrows, Richard ; Lefaucheur, Carmen ; Loupy, Alexandre ; Stegall, Mark D. / Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor : Implications for clinical trials. In: American Journal of Transplantation. 2019.
@article{0c0091ff41a84641af838bf62fc26581,
title = "Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials",
abstract = "Predicting which renal allografts will fail and the likely cause of failure is important in clinical trial design to either enrich patient populations to be or as surrogate efficacy endpoints for trials aimed at improving long-term graft survival. This study tests our previous Birmingham-Mayo model (termed the BirMay Predictor) developed in a low-risk kidney transplant population in order to predict the outcome of patients with donor specific alloantibody (DSA) at the time of transplantation and identify new factors to improve graft loss prediction in DSA+ patients. We wanted define ways to enrich the population for future therapeutic intervention trials. The discovery set included 147 patients from Mayo Cohort and the validation set included 111 patients from the Paris Cohort—all of whom had DSA at the time of transplantation. The BirMay predictor performed well predicting 5-year outcome well in DSA+ patients (Mayo C statistic = 0.784 and Paris C statistic = 0.860). Developing a new model did not improve on this performance. A high negative predictive value of greater than 90{\%} in both cohorts excluded allografts not destined to fail within 5 years. We conclude that graft-survival models including histology predict graft loss well, both in DSA+ cohorts as well as DSA- patients.",
keywords = "alloantibody, clinical research/practice, kidney (allograft) function/dysfunction, kidney transplantation/nephrology, pathology/histopathology, protocol biopsy, risk assessment/risk stratification",
author = "Andrew Bentall and Smith, {Byron H.} and Gonzales, {Manuel Moreno} and Keisha Bonner and Park, {Walter D.} and Cornell, {Lynn D.} and Dean, {Patrick G.} and Carrie Schinstock and Richard Borrows and Carmen Lefaucheur and Alexandre Loupy and Stegall, {Mark D}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ajt.15312",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor

T2 - Implications for clinical trials

AU - Bentall, Andrew

AU - Smith, Byron H.

AU - Gonzales, Manuel Moreno

AU - Bonner, Keisha

AU - Park, Walter D.

AU - Cornell, Lynn D.

AU - Dean, Patrick G.

AU - Schinstock, Carrie

AU - Borrows, Richard

AU - Lefaucheur, Carmen

AU - Loupy, Alexandre

AU - Stegall, Mark D

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Predicting which renal allografts will fail and the likely cause of failure is important in clinical trial design to either enrich patient populations to be or as surrogate efficacy endpoints for trials aimed at improving long-term graft survival. This study tests our previous Birmingham-Mayo model (termed the BirMay Predictor) developed in a low-risk kidney transplant population in order to predict the outcome of patients with donor specific alloantibody (DSA) at the time of transplantation and identify new factors to improve graft loss prediction in DSA+ patients. We wanted define ways to enrich the population for future therapeutic intervention trials. The discovery set included 147 patients from Mayo Cohort and the validation set included 111 patients from the Paris Cohort—all of whom had DSA at the time of transplantation. The BirMay predictor performed well predicting 5-year outcome well in DSA+ patients (Mayo C statistic = 0.784 and Paris C statistic = 0.860). Developing a new model did not improve on this performance. A high negative predictive value of greater than 90% in both cohorts excluded allografts not destined to fail within 5 years. We conclude that graft-survival models including histology predict graft loss well, both in DSA+ cohorts as well as DSA- patients.

AB - Predicting which renal allografts will fail and the likely cause of failure is important in clinical trial design to either enrich patient populations to be or as surrogate efficacy endpoints for trials aimed at improving long-term graft survival. This study tests our previous Birmingham-Mayo model (termed the BirMay Predictor) developed in a low-risk kidney transplant population in order to predict the outcome of patients with donor specific alloantibody (DSA) at the time of transplantation and identify new factors to improve graft loss prediction in DSA+ patients. We wanted define ways to enrich the population for future therapeutic intervention trials. The discovery set included 147 patients from Mayo Cohort and the validation set included 111 patients from the Paris Cohort—all of whom had DSA at the time of transplantation. The BirMay predictor performed well predicting 5-year outcome well in DSA+ patients (Mayo C statistic = 0.784 and Paris C statistic = 0.860). Developing a new model did not improve on this performance. A high negative predictive value of greater than 90% in both cohorts excluded allografts not destined to fail within 5 years. We conclude that graft-survival models including histology predict graft loss well, both in DSA+ cohorts as well as DSA- patients.

KW - alloantibody

KW - clinical research/practice

KW - kidney (allograft) function/dysfunction

KW - kidney transplantation/nephrology

KW - pathology/histopathology

KW - protocol biopsy

KW - risk assessment/risk stratification

UR - http://www.scopus.com/inward/record.url?scp=85062999369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062999369&partnerID=8YFLogxK

U2 - 10.1111/ajt.15312

DO - 10.1111/ajt.15312

M3 - Article

C2 - 30768833

AN - SCOPUS:85062999369

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -